Convalescent plasma or hyperimmune immunoglobulin for people with COVID‐19
CITATION: Nnaji, C. A. et al. 2020. Convalescent plasma or hyperimmune immunoglobulin for people with COVID‐19. South African Medical Journal, 110(8):759-760, doi:10.7196/SAMJ.2020.v110i8.15032.
The original publication is available at http://www.samj.org.za
Convalescent plasma is being considered as a potential therapy for COVID‐19. We highlight and contextualise the findings of a recent Cochrane rapid review that evaluated the effectiveness and safety of convalescent plasma or hyperimmune immunoglobulin transfusion in the treatment of people with COVID‐19. The review found low‐certainty evidence of the therapeutic effectiveness and safety of convalescent plasma. As the novel coronavirus continues to spread in South Africa (SA), convalescent plasma may offer a therapeutic ray of hope for mitigating the morbidity and mortality burdens of the disease. Further investigation of the clinical benefits of the therapy in well-designed studies is needed to provide more evidence that will guide COVID-19 treatment decision-making in the SA context.
- Collection B